Yolia Health provides a non‑invasive, drug‑free biomedical device that delivers the True Vision Treatment® to restore near‑vision acuity in presbyopic adults within three days. The clinic‑based protocol reshapes the eye’s focusing ability, eliminating the need for reading glasses or surgical correction.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Presbyopia affects virtually everyone over age 50, leading to a growing demand for near‑vision correction. Traditional solutions rely on reading glasses or invasive surgical procedures, which can be inconvenient, costly, or carry health risks.
Solution
Yolia Health offers a non‑invasive biomedical device that delivers a rapid, repeatable treatment to improve near vision. The protocol, called True Vision Treatment®, restores functional vision within three days without the need for glasses or surgery. The device applies a targeted therapy that reshapes the eye’s focusing ability, providing a safe alternative to conventional corrective methods. Patients receive the treatment in a clinical setting and can resume normal activities immediately after the short course.
Target Audience
Primary customers are adults over 50 experiencing presbyopia who seek an alternative to glasses or surgical correction, as well as eye‑care clinics and vision‑health providers offering non‑invasive treatment options.
Features
- Non‑surgical, drug‑free treatment using a proprietary biomedical device
- Treatment course completed in three days with a single, repeatable session
- Clinically administered protocol designed to restore near‑vision acuity
- No requirement for glasses or contact lenses post‑treatment
- Designed for adults with age‑related presbyopia, applicable across a broad demographic